Expert Review of Anticancer Therapy

Article	Citations
Prognostic impact of renin-angiotensin system inhibitors in patients with ovarian cancer: a meta-analysis of real-world evidence	85
Clinical characteristics and outcomes among patients with subcutaneous panniculitis-like T-cell lymphoma	72
An evaluation of nivolumab plus gemcitabine and cisplatin in the treatment of advanced urothelial carcinoma	53
Nanotechnology meets liver cancer: liposomal immunotherapy strategies for hepatocellular carcinoma	44
Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?	44
Prevailing challenges in personalized treatment for metastatic renal cell carcinoma: a narrative review	42
Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review	40
Oral decitabine and cedazuridine for the treatment of myelodysplastic syndromes: an integrated review of clinical, economic and patient-centered evidence	36
PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects	33
Effect of steroid therapy on survival in patients with metastatic solid tumors experiencing immune-related adverse events	28
Current status and novel insights into the role of metastasectomy in the era of immunotherapy	28
Efficacy and toxicity of drugs targeting KRAS G12C mutation in non-small cell lung cancer: a meta-analysis	22
Use of Razoxane as a radiosensitizer for the treatment of soft tissue sarcomas	20
Importance of radiation-related cognitive decline in older adults who receive cranial radiation	19
Palbociclib in endocrine-resistant metastatic breast cancer: real-world outcomes	19
Progress in histology specific treatments in soft tissue sarcoma	18
Prognostic and clinicopathological value of myeloid-derived suppressor cells in lung cancer: a comprehensive systematic review and meta-analysis	17
Current diagnostic and therapeutic options in de novo low-volume metastatic hormone-sensitive prostate cancer	17
Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer	17
The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan	16
Current management of familial adenomatous polyposis	15
Polypharmacy, polypharmacology, and polypharmacotherapy: clarifying definitions and complementary roles in cancer treatment – a narrative review	15
Prognostic factors of undifferentiated embryonal sarcoma of the liver in children: a SEER-based study	14
Supportive care in pediatric acute myeloid leukemia:Expert-based recommendations of the NOPHO-DB-SHIP consortium	14
Primary effusion lymphoma: therapeutic strategies targeting viral and cellular mechanisms	14

An evaluation of selinexor as a maintenance therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma	13
Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population	13
Safety and efficacy of immune checkpoint inhibitors in patients with cancer and hepatitis B: multicentre experience in a low-middle-income country	13
The importance of autophagy in multiple myeloma	13
NRF2/KEAP1 signaling inhibitors in gynecologic cancers	13
Determining factors of neuroplasticity in patients with brain tumors: impact of connectome and artificial intelligence. A narrative review	13
Elacestrant in metastatic breast cancer: current advancements and future perspectives	13
EGFR-TKI plus chemotherapy versus TKI monotherapy in advanced EGFR-mutant NSCLC with high PD-L1 expression: a real-world retrospective study	13
CDK4/6 inhibition in early and advanced hormone receptor-positive, HER2-negative breast cancer	13
A systematic review to summarize treatment patterns, guidelines, and characteristics of patients with renal cell carcinoma in the Asia-Pacific region	12
Current status of robotic surgery for hepato-pancreato-biliary malignancies	12
Deciding individual treatment for primary retroperitoneal sarcoma	12
Prostate cancer prediction through a hybrid deep learning method applied to histopathological image	12
What are the key considerations for deciding on the use of CAR T-cell therapy for patients with follicular lymphoma?	12
The long and winding road of faecal microbiota transplants to targeted intervention for improvement of immune checkpoint inhibition therapy	11
Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives	11
Prevalence and molecular correlates of acquired EGFR resistance mutations in non-small cell lung cancer (NSCLC)	11
NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime?	11
Evaluating the efficacy and safety of trebananib in treating ovarian cancer and non-ovarian cancer patients: a meta-analysis and systematic review	11
From macroscopic clearance to molecular eradication: paradigm shift and future perspectives in the detecting of residual lesions after transurethral resection of bladder tumors	11
Targeting GPRC5D in multiple myeloma	11
The trend toward more target therapy in pancreatic ductal adenocarcinoma	11
Efficacy of third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in advanced NSCLC with different T790M statuses tested via digital droplet polymerase chain reaction ddPCR and	11
PROTACs in action: a novel strategy for pancreatic cancer	11
The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer	11
Unveiling the power of PARP inhibitors: a meta-analysis on newly diagnosed advanced ovarian cancer maintenance therapy	11
Management of breast cancer diagnosed during pregnancy: global perspectives	11
CRISPR: a precise genome editing strategy for the treatment of hepatocellular carcinoma	11
Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity	11
Nivolumab plus ipilimumab in malignant pleural mesothelioma	11
Outcomes after the watch-and-wait strategy and local excision treatment for rectal cancer: a meta-analysis	11
Novel breakthroughs in advanced prostate cancer management	10
Anticancer properties of histone deacetylase inhibitors – what is their potential?	10
Real-world treatment patterns and survival in advanced/metastatic triple-negative breast cancer in Japan	10
Interventions to reduce the risk of side-effects of cancer treatments in childhood	10
Differentiated thyroid cancer and positron emission computed tomography: when, how and why?	10
Optic glioma in children: clinical presentation, diagnosis, and management	10
What’s to come in PSMA therapies and diagnostics: A summary of clinical trials involving PSMA radioligand-based therapeutic and/or diagnostic approaches with active recruitment	10
Pretreatment hyperferritinaemia as an independent prognostic marker in metastatic solid tumors treated with immune checkpoint inhibitors	10
Drug–drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors	10
Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond	10
Efficacy and safety of anti-angiogenesis agents combined with chemoradiotherapy in the treatment of locally advanced cervical cancer: a meta-analysis of randomized controlled trials	10
A neurocentric model of survivorship: rethinking success when the mind and nerves don’t recover	10
Emerging treatment options for prostate cancer	9
JARID2 activation by NFYA promotes stemness of triple-negative breast cancer cells through the PI3K/AKT pathway	9
Drugging the DNA damage response in the clinic: going beyond PARP	9
Benign and malignant cardiac masses: long-term outcomes after surgical resection	9
Understanding the causes of recurrent HCC after liver resection and radiofrequency ablation	9
First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR -mutated NSCLC: a meta-analysis of randomized phase III trials	9
Genetic investigation in patients with histological variants of bladder cancer: clinical implications	9

Upper and lower limb cryotherapy as a preventive strategy for taxane-induced peripheral neuropathy in breast cancer patients: a systematic review and meta-analysis	9
Polypharmacy is the hidden co-treatment in oncology	9
Pembrolizumab for the adjuvant treatment of IIB or IIC melanoma	8
Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer	8
Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers	8
Immune checkpoint inhibitors in urothelial carcinoma: a practical framework for patient selection, toxicity management, response assessment, and treatment sequencing	8
Clinicopathological and prognostic significance of TIMP1 expression in gastric cancer: a systematic review and meta-analysis	8
Compression therapy for the prevention of taxane-induced peripheral neuropathy in breast cancer: a systematic review and meta-analysis	8
Image-guided radiotherapy (IGRT) in Lombardy, Italy: a survey by the Lombardy section of the Italian Association of Radiotherapy and Clinical Oncology (AIRO-Lombardy)	8
Radiation-induced nasopharyngeal necrosis combined with local recurrence in nasopharyngeal carcinoma: diagnosis and treatment strategies	8
The Gustave Roussy immune score as a novel biomarker for predicting survival in patients with isocitrate dehydrogenase wild-type glioblastoma treated with the Stupp protocol	8
Effect of flexible sigmoidoscopy-based screening on colorectal cancer incidence and mortality: an updated systematic review and meta-analysis of randomized controlled trials	7
CRISPR–mRNA synergy: toward adaptive cancer immunotherapy	7
Immune checkpoint inhibition in early-stage triple-negative breast cancer	7
Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?	7
ESMO 2025 and new therapies in breast cancer: does society always benefit?	7
Venetoclax and beyond: New Horizons in CLL and AML therapy	7
Epigenetic targeting in oral squamous cell carcinoma: mechanisms, therapies, and translational potential	7
Oligometastases in head and neck squamous cell carcinoma patients	7
Girentuximab imaging in renal cancer: diamond in the rough or just ZIRCON?	7
Shedding light on the side effects of immunotherapies used for leukemia: an updated review of the literature	7
Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?	7
Ablative margins in percutaneous thermal ablation of hepatic tumors: a systematic review	6
From supportive care to adjunctive treatment: the evolution in time of physical exercise and nutrition in lung cancer	6
Is the ketogenic diet still controversial in cancer treatment?	6
Reevaluating the promise: is primary tumor surgery really the key to survival or just a misinterpretation in de novo stage IV breast cancer?	6
The assessment of circulating tumor DNA associated with Wnt/β-catenin signaling pathway as a diagnostic tool for liver cancer: a systematic review and meta-analysis	6
Is 2045 the best we can do? Mitigating the HPV-related oropharyngeal cancer epidemic	6
Future directions for antibody-drug conjugates in urothelial cancer	6
The current treatment approach to adolescents and young adults with acute lymphoblastic leukemia (AYA-ALL): challenges and considerations	6
Utilizing risk factors to guide treatment decisions in chronic lymphocytic leukemia	6
Contemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) tumor microenvironment	6
The selection of targeted therapies for relapsed or refractory advanced renal cell carcinoma	6
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer?	6
Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy	6
Mucosa-associated lymphoid tissue lymphoma in thymus: a SEER analysis	6
Circadian rhythm-based cancer therapy in randomised clinical trials	6
Overcoming common emerging barriers to effective neoadjuvant immunotherapies	6
Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer	6
From budget constraints to value-based payment: an incremental cost-effectiveness analysis of sacituzumab tirumotecan for advanced triple-negative breast cancer in China	6
Post-operative serum CEA predicts prognosis in HR-positive/HER2-negative early breast cancer	6
Contemporary management of advanced gastric and gastroesophageal adenocarcinomas	6
Pembrolizumab trough concentration monitoring and association with outcomes in advanced non-small cell lung cancer	6
An evaluation of pembrolizumab with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)	6
Hepatic artery infusion chemotherapy combined with the FOLFOX regimen for the treatment of hepatocellular carcinoma: recent advances and literature review	6
Inhibition of neuroactive ligand–receptor interaction pathway can enhance immunotherapy response in colon cancer: an in silico study	6
First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC	6
Predicting neoadjuvant chemoradiotherapy response with functional imaging and liquid biomarkers in locally advanced rectal cancer	6
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma	6
Management of oligometastatic and oligoprogressive renal cell carcinoma: an updated review	6
A nephrology perspective on the clinical impact and management of delayed high-dose methotrexate elimination	6
Medullary thyroid carcinoma: a narrative historical review	6
The relationship between statin use and breast cancer risk: NHANES 2003–2016 and Mendelian randomization study	6
Fixed-duration BTKi-venetoclax combinations in CLL: optimizing patient-centered care	6
The association between HALP score and survival in patients treated with immune checkpoint inhibitors	6
Learning from late-stage trial failures in higher-risk myelodysplastic syndromes: towards adaptive and biomarker-enriched designs	5
Recent advances in the management of intrahepatic cholangiocarcinoma: the role of actionable mutations and targeted therapies	5
RASGEF1C affects aerobic glycolysis and facilitates lung cancer progression through the PLK1 signaling pathway	5
Safety of PD-L1 inhibitors versus PD-1 inhibitors in the treatment of lung cancer: a systematic review and network meta-analysis	5
The multidisciplinary management of locally advanced rectal cancer	5
Diagnostic performance of urine and blood microRNAs for bladder cancer: a meta-analysis	5
Complications following small-molecule inhibitors for non-small cell lung cancer	5
Therapeutic patterns and outcomes in older patients (aged≥65 years) with stage III-IVB inoperable oral cavity squamous cell carcinoma (OCSCC): an investigational study from the SEER database	5
Prognostic value of circulating long non-coding RNAs in colorectal cancer patients: a meta-analysis	5
Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for gastric cancer treatment: a systematic review and meta-analysis	5
Primary site and treatment impact in unresectable metastatic colorectal cancer	5
Concomitant use of H1 antihistamines improves survival outcomes in cancer patients on immune checkpoint inhibitor therapy: a systematic review and meta-analysis	5
Safety and hematological toxicities of PARP inhibitors in patients with cancer: a systematic review of randomized controlled trials and a pharmacovigilance analysis	5
Integrating PET/CT into breast cancer care: a review of recent developments	5
Toward clinical translation of AI-Led drug discovery in endometrial cancer	5
PSMA PET or conventional imaging in metastatic hormone-sensitive prostate cancer?	5
Analysis of the efficacy of paclitaxel combined with bevacizumab intraperitoneal instillation in common gastrointestinal malignant peritoneal effusions and screening of prognostic indicators	5
Clarifications and comments on “infrared radiation for cancer hyperthermia: the light to brighten up oncology”	5
FLT3 -mutated AML: immune evasion through exosome-mediated mechanisms and innovative combination therapies targeting immune escape	5
The role of planetary health in urologic oncology	5
The investigational role of cytoreductive stereotactic ablative radiation therapy (SABR) to the primary tumor in metastatic kidney cancer	5
Emerging immune checkpoint inhibitor strategies in cervical cancer: a scoping review of ongoing clinical trials	5
Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: a systematic review and meta-analysis	5
Pathology, molecular biology, medical oncology, and radiotherapy implications of lung neuroendocrine neoplasm classification: a multidisciplinary perspective	5
Oral selective estrogen receptor degraders (SERDs) in hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4/6 inhibitors	5

Development of a nomogram for predicting postoperative recurrence of cervical intraepithelial neoplasia using immunohistochemical and clinical parameters	5
Cancer immunotherapy efficacy and machine learning	5
Current and emerging treatment options for BRAFV600-mutant melanoma	5
An evaluation of vimseltinib for treatment of tenosynovial giant cell tumors	5
Prognostic value of the body composition parameters in patients with colorectal liver metastases undergoing intra-arterial treatment	5
Mirdametinib in symptomatic neurofibromatosis type 1 plexiform neurofibromas	5
Relugolix in the management of prostate cancer	5
How can we refine the prognostic stratification of triple-negative breast cancer?	5
Addressing the need for more therapeutic options in neuroendocrine prostate cancer	5
Multidisciplinary systemic and local therapies for metastatic renal cell carcinoma: a narrative review	5
Efficacy of doxorubicin and lipiodol therapy by trans-arterial chemoembolization in hepatocellular carcinoma Egyptian patients and relation to genetic polymorphisms	5
Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment	4
How can we address the challenge of distant metastases in HNSCC prognosis?	4
Prognostic value of the nodal yield in oral squamous cell carcinoma: a systematic review and meta-analysis	4
Medical imaging and multimodal artificial intelligence models for streamlining and enhancing cancer care: opportunities and challenges	4
Tebentafusp for the treatment of HLA-A*02:01–positive adult patients with unresectable or metastatic uveal melanoma	4
Immune checkpoint inhibitor resumption after discontinuation due to immune-related adverse events: a nomogram-based analysis of risk factors and outcomes	4
Prognostic and clinicopathological value of CDK12 mutation in prostate cancer: a meta-analysis	4
Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges	4
The evolving survival landscape in advanced non-small cell lung cancer: an interrupted time series analysis	4
Bevacizumab-containing treatment for relapsed or refractory Wilms tumor	4
Desmoplastic small round cell tumor: from state of the art to future clinical prospects	4
Neutrophil-to-lymphocyte ratio predicts survival of patients with rectal cancer receiving neo-adjuvant chemoradiation followed by radical resection: a meta-analysis	4
Allogeneic transplantation and cellular therapies in cutaneous T-cell lymphoma	4
Factors influencing survival in metastatic castration-resistant prostate cancer therapy	4
Advanced delivery of leuprorelin acetate for the treatment of prostatic cancer	4
Targeted therapies in advanced biliary malignancies: a clinical review	4
Association between CD8+ tumor-infiltrating lymphocytes and prognosis of non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis	4
Zolbetuximab as a gastric lineage-directed immunotherapy: mechanistic rationale and translational evidence in CLDN18.2-positive gastroesophageal adenocarcinoma	4
A systematic review on clinical pharmacokinetics and pharmacodynamics of antiangiogenic tyrosine kinase inhibitors (TKIs) with high TDM scores	4
Efficacy and safety of chemotherapy regimens for first-line treatment of advanced esophageal squamous cell carcinoma in Asia: a systematic review	4
Burden trends and risk factors for prostate cancer from 1990 to 2021: a systematic analysis of the Global Burden of Disease Study 2021	4
Optimizing adjuvant and post-neoadjuvant therapy in HER2-positive early breast cancer	4
Balancing efficacy with long-term side-effects: can we safely de-escalate therapy for germ cell tumors?	4
Harnessing the power of artificial intelligence for clinical trials in cancer	4
Clear cell sarcoma: state-of-the art and perspectives	4
A meta-analysis of UCA1 accuracy in the detection of bladder cancer	4
The role of immune checkpoint inhibitors in the management of NMIBC: a scoping review of current status and future direction	4
Implementation of a CAR-T cell therapy program in India	4
Efficacy and safety of neoadjuvant therapy for triple-negative breast cancer: a Bayesian network meta-analysis	4
G-CSF for managing venetoclax-related neutropenia in acute myeloid leukemia	4
Liposomal nanomedicine in cancer therapy: advances in drug delivery	4
Understanding the link between aspartame and cancer	4
Advances and future directions in radiopharmaceutical delivery for cancer treatment	4
Molecular subtype identification and prognosis stratification by a immunogenic cell death-related gene expression signature in colorectal cancer	4
The role of immunotherapy plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-small cell lung cancer: an updated systematic review and meta-analysis of randomized cont	4
Treatment of basal cell carcinoma with intralesional interferon alfa-2b: an open-label clinical trial	4
The evolving role of multidisciplinary teams in optimizing non-muscle invasive bladder cancer care	4
Recent advances in photodynamic therapy combined with chemotherapy for cervical cancer: a systematic review	4
Immune senescence in non-small cell lung cancer management: therapeutic relevance, biomarkers, and mitigating approaches	4
The new insights of surgery for locally advanced head and neck cancer	3
The prognostic significance of lymph node metastases characteristics in papillary thyroid carcinoma: a scoping review	3
LUMINATE-101-Maccabi: a real-world study of treatment patterns and clinical outcomes in patients with non-squamous metastatic non-small cell lung cancer in an Israeli Health Maintenance Organization (	3
The PI3K signaling pathway; from normal lymphopoiesis to lymphoid malignancies	3
The role of PSMA PET/CT imaging in identifying low-risk prostate cancer candidates for active surveillance after biopsy	3
The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2 -mutant NSCLC: a bench-to-bedside review	3
Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment	3
Implementing machine learning to predict survival outcomes in patients with resected pulmonary large cell neuroendocrine carcinoma	3
PARP inhibitor resistance mechanisms and PARP inhibitor derived imaging probes	3
Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab	3
Increasing the accuracy of colorectal cancer screening	3
Efficacy and safety of neoadjuvant combination immunotherapy in surgically resectable malignant solid tumors: a systematic review and meta-analysis	3
Hot topics in renal cancer pathology: implications for clinical management	3
Positron emission computed tomography targeting urokinase plasminogen activator receptor (uPAR) in cancer: a systematic review	3
The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a system	3
Human oncogenic viruses: an overview of protein biomarkers in viral cancers and their potential use in clinics	3
Medullary thyroid carcinoma	3
Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma	3
Melanoma neoadjuvant treatment: review and update of recent trials	3
Effectiveness and cost-effectiveness of first-line versus second-line use of repotrectinib in the treatment of ROS1 fusion-positive advanced NSCLC	3
Synergistic strategies: histone deacetylase inhibitors and platinum-based drugs in cancer therapy	3
Olaparib targets Ubiquitin D to promote autophagy in hepatocellular carcinoma by regulating glutamine metabolism	3
Efficacy and safety analysis of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) in the treatment of osteosarcoma: a systematic review and meta-analysis	3
Radiation therapy for triple-negative breast cancer: from molecular insights to clinical perspectives	3
Novel therapies for metastatic prostate cancer	3
Overview and recent advances in incidental meningioma	3
Opportunities and challenges in the clinical application of anticancer virotherapy	3
Surgery versus radiotherapy for older patients (aged≥65 years) with stage I-II laryngeal cancer: an investigational study from the SEER database	3
Quality of life in ovarian cancer patients receiving maintenance therapy with bevacizumab versus PARPi: a network meta-analysis	3
Risk factors for secondary neoplasms in retinoblastoma survivors: a systematic literature review	3
Re-irradiation for recurrent/progressive pediatric brain tumors: from radiobiology to clinical outcomes	3
Neopterin as a potential prognostic and predictive biomarker in metastatic renal cell carcinoma treated with immune checkpoint inhibitors	3
Post-CDK4/6 inhibitor treatment landscape in metastatic hormone receptor-positive breast cancer: a narrative review	3
Consideration of quality of life in the treatment decision-making for patients with advanced gastroenteropancreatic neuroendocrine tumors	3
Can we consider stopping hepatocellular carcinoma surveillance in low-risk patients with hepatitis B?	3
Clinical management of oligoprogressive renal cell carcinoma	3
Current usage of pembrolizumab in triple negative breast cancer (TNBC)	3
Impact of renin–angiotensin system inhibitors on the clinical outcomes of nivolumab therapy in metastatic non–small cell lung cancer	3
Advancing patient-centered care in myelodysplastic syndromes/neoplasms with oral therapies	3
Association of RAD51 expression with response to neoadjuvant treatment and prognosis in locally advanced gastric cancer	3
Optimizing cystectomy outcomes in muscle-invasive bladder cancer: what’s new in 2025?	3
The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities, and future directions	3
Lisocabtagene maraleucel for relapsed or refractory large B-cell non-Hodgkin lymphoma	3
The clinical utility of molecular residual disease testing in early-stage breast cancer	3
Immunotherapy with chemotherapy and anti-angiogenic therapy for EGFR mutated NSCLC: challenging the dogma	3